NO304968B1 - Spiselig sammensetning for reduksjon av serumlipidnivÕer eller reduksjon av °kning i blodglukosenivÕ etter mÕltid, samt dens fremstilling - Google Patents

Spiselig sammensetning for reduksjon av serumlipidnivÕer eller reduksjon av °kning i blodglukosenivÕ etter mÕltid, samt dens fremstilling

Info

Publication number
NO304968B1
NO304968B1 NO933101A NO933101A NO304968B1 NO 304968 B1 NO304968 B1 NO 304968B1 NO 933101 A NO933101 A NO 933101A NO 933101 A NO933101 A NO 933101A NO 304968 B1 NO304968 B1 NO 304968B1
Authority
NO
Norway
Prior art keywords
levels
blood glucose
reducing
compositions
meals
Prior art date
Application number
NO933101A
Other languages
English (en)
Norwegian (no)
Other versions
NO933101L (no
NO933101D0 (no
Inventor
Jennifer B Dressman
Christos Reppas
Stephen W Tobey
Cynthia W Sowle
Original Assignee
Univ Michigan
Dow Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27098725&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO304968(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Michigan, Dow Chemical Co filed Critical Univ Michigan
Publication of NO933101D0 publication Critical patent/NO933101D0/no
Publication of NO933101L publication Critical patent/NO933101L/no
Publication of NO304968B1 publication Critical patent/NO304968B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D13/00—Finished or partly finished bakery products
    • A21D13/80—Pastry not otherwise provided for elsewhere, e.g. cakes, biscuits or cookies
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
    • A21D2/14—Organic oxygen compounds
    • A21D2/18—Carbohydrates
    • A21D2/188—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
NO933101A 1991-03-01 1993-08-31 Spiselig sammensetning for reduksjon av serumlipidnivÕer eller reduksjon av °kning i blodglukosenivÕ etter mÕltid, samt dens fremstilling NO304968B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66338191A 1991-03-01 1991-03-01
US87060192A 1992-02-21 1992-02-21
PCT/US1992/001515 WO1992015312A1 (en) 1991-03-01 1992-02-28 Pharmaceutical compositions and uses of water-soluble, high-viscosity grade cellulose ethers

Publications (3)

Publication Number Publication Date
NO933101D0 NO933101D0 (no) 1993-08-31
NO933101L NO933101L (no) 1993-10-19
NO304968B1 true NO304968B1 (no) 1999-03-15

Family

ID=27098725

Family Applications (1)

Application Number Title Priority Date Filing Date
NO933101A NO304968B1 (no) 1991-03-01 1993-08-31 Spiselig sammensetning for reduksjon av serumlipidnivÕer eller reduksjon av °kning i blodglukosenivÕ etter mÕltid, samt dens fremstilling

Country Status (16)

Country Link
EP (1) EP0502666B2 (de)
JP (1) JP3436537B2 (de)
KR (1) KR100227002B1 (de)
AT (1) ATE206927T1 (de)
AU (2) AU669654B2 (de)
CA (1) CA2062091C (de)
DE (1) DE69232126T3 (de)
ES (1) ES2168256T3 (de)
FI (1) FI933809A7 (de)
HU (1) HU222487B1 (de)
IE (1) IE920660A1 (de)
IL (1) IL101113A (de)
MX (1) MX9200888A (de)
NO (1) NO304968B1 (de)
NZ (1) NZ241778A (de)
WO (1) WO1992015312A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721221A (en) * 1991-03-08 1998-02-24 Regents Of The University Of Minnesota Lowering blood cholesterol levels using water soluble cellulose ethers
US5281584A (en) * 1992-02-28 1994-01-25 The Dow Chemical Company Effect of particle-size distribution of cellulose ethers on palatability of compositions
US6432442B1 (en) 1998-02-23 2002-08-13 Mcneil-Ppc, Inc. Chewable product
US6899892B2 (en) 2001-12-19 2005-05-31 Regents Of The University Of Minnesota Methods to reduce body fat
CN101686994B (zh) * 2006-10-20 2013-05-01 陶氏环球技术公司 水溶性纤维素衍生物制备用于预防或治疗代谢综合征的药物等的用途
ITFI20120268A1 (it) 2012-12-03 2014-06-04 Diopeite Consulting Ltd Composizioni farmaceutiche per il trattamento dell'obesita'
US20160231334A1 (en) * 2013-10-28 2016-08-11 The Forsyth Institute Compositions and Methods for Evaluating Metabolic Syndrome and Related Diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802741A (en) 1953-09-21 1957-08-13 Dow Chemical Co Cake mixes containing water-soluble cellulose ethers
US3709876A (en) * 1972-04-10 1973-01-09 Dow Chemical Co Water soluble hydroxyethyl methyl cellulose ether thickener for latex paint
US4284649A (en) 1977-11-22 1981-08-18 Wiczer Sol B Thickened gelatinous edible alcoholic medicated carrier
US4451490A (en) * 1982-03-08 1984-05-29 General Foods Corporation High quality, reduced-calorie cake containing cellulose and process thereof
NZ207125A (en) * 1983-02-17 1986-07-11 Merrell Pharma Inc Bulk laxative composition containing water-soluble cellulose ether
FI895708A7 (fi) * 1989-02-10 1990-08-11 Alko Ab Oy Vesiliukoinen hajoamistuote

Also Published As

Publication number Publication date
HU222487B1 (hu) 2003-07-28
JP3436537B2 (ja) 2003-08-11
NZ241778A (en) 1995-04-27
NO933101L (no) 1993-10-19
KR100227002B1 (ko) 1999-10-15
WO1992015312A1 (en) 1992-09-17
DE69232126T3 (de) 2008-07-17
IL101113A (en) 1999-11-30
EP0502666B1 (de) 2001-10-17
AU689035B2 (en) 1998-03-19
IE920660A1 (en) 1992-09-09
CA2062091A1 (en) 1992-09-02
EP0502666B2 (de) 2007-11-21
ATE206927T1 (de) 2001-11-15
AU1127492A (en) 1992-08-27
FI933809L (fi) 1993-10-01
EP0502666A1 (de) 1992-09-09
JPH06507393A (ja) 1994-08-25
IL101113A0 (en) 1992-11-15
NO933101D0 (no) 1993-08-31
DE69232126T2 (de) 2002-06-27
ES2168256T3 (es) 2002-06-16
FI933809A7 (fi) 1993-10-01
MX9200888A (es) 1994-07-29
DE69232126D1 (de) 2001-11-22
AU5200096A (en) 1996-07-18
FI933809A0 (fi) 1993-08-31
AU669654B2 (en) 1996-06-20
CA2062091C (en) 2002-12-17
HUT67327A (en) 1995-03-28

Similar Documents

Publication Publication Date Title
US11213543B2 (en) Human gastrointestinal microbiome modulating composition and methods of use
Fu et al. Bioavailability of tocotrienols: evidence in human studies
Mitra et al. Cholesterol solubilization in aqueous micellar solutions of quillaja saponin, bile salts, or nonionic surfactants
Cigarrán Guldris et al. Fibre intake in chronic kidney disease: what fibre should we recommend?
Cheung et al. Lipid-lowering nutraceuticals for an integrative approach to dyslipidemia
JPS5948414A (ja) ビタミンｅの水溶性製剤
Corrêa et al. The intake of fiber mesocarp passionfruit (Passiflora edulis) lowers levels of triglyceride and cholesterol decreasing principally insulin and leptin
WO2004080470A1 (ja) 肥満予防・改善剤
NO304968B1 (no) Spiselig sammensetning for reduksjon av serumlipidnivÕer eller reduksjon av °kning i blodglukosenivÕ etter mÕltid, samt dens fremstilling
US5145678A (en) Method of reducing blood serum cholesterol
Hoie et al. Cholesterol-lowering effects of a new isolated soy protein with high levels of nondenaturated protein in hypercholesterolemic patients
Helal Progressive effects of the interaction of sodium nitrite and sunset yellow on different physiological parameters in albino rats
DE2935546C2 (de) Diätetische Lebensmittel mit Monoglyceriden von Fettsäuren
Awazu et al. The herbal medicine Sairei-to inhibits proliferation of rat mesangial cells
EP0745332A1 (de) Klinische Nährungszusammensetzung
JPH078803B2 (ja) 低コレステロール血症治療剤
FI113613B (fi) Elintarvikekoostumukset ja menetelmiä niiden valmistamiseksi
AZANDO Feeding Rabbits (Oryctolagus cuniculus) Based on Ocimum gratissimum and Vernonia amygdalina Leaves in West Africa: Biochemical and Hematological Aspects
RU2740374C2 (ru) Способ коррекции состояния больных артериальной гипертонией и ожирением
WO2003011309A2 (de) Verwendung einer calciumhaltigen pharmazeutischen zusammensetzung zur behandlung von hypercholesterinämie
JPH08208464A (ja) 高脂血症の治療及び予防薬
US20170239306A1 (en) Soybean extracts and combinations thereof with polyethoxylated castor oil and other adjuvants for controling blood sugar levels and for hepatoprotection
Gilroy The role of fat ingested in the diet in the incidence of Sprue
McCarrison Remarks On Diseases Of Faulty Nutrition
Razavizadeh et al. A Comparison of the Therapeutic Effects of Pioglitazone and Metformin in Non-alcoholic Steatohepatitis

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees